<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">EPROSARTAN MESYLATE</span><br/>(e-pro-sar'tan)<br/><span class="topboxtradename">Teveten<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">angiotensin ii receptor antagonist</span>; <span class="classification">antihypertensive</span><br/><b>Prototype: </b>Losartan potassium<br/><b>Pregnancy Category: </b>C (first trimester); D (second and third trimester)<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>400 mg, 600 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Angiotensin II receptor (type AT<sub>1</sub>) antagonist. Angiotensin II is a potent vasoconstrictor and primary vasoactive hormone of the renin-angiotensin-aldosterone
         system.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Selectively blocks the binding of angiotensin II to the AT<sub>1</sub> receptors found in many tissues. This blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II, thus
         resulting in an antihypertensive effect. This is indicated by decreases in systolic and diastolic BP.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of hypertension.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to eprosartan, losartan or other angiotensin II receptor antagonists; pregnancy [(category C) first trimester,
         and (category D) second and third trimesters], lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Angioedema, aortic or mitral value stenosis, coronary artery disease, cardiomyopathy, hypotension, CHF; biliary obstruction;
         older adults; hepatic dysfunction, renal artery stenosis, renal impairment.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 600 mg q.d. or 400 mg q.d. to b.i.d. (max: 800 mg/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Correct volume depletion prior to therapy to prevent hypotension.</li>
<li>Store at 15°30° C (59°86° F); protect from moisture and direct light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Viral infection, fatigue, arthralgia. <span class="typehead"> CNS:</span> Depression. <span class="typehead"> GI:</span> Abdominal pain, hypertriglyceridemia. <span class="typehead">Respiratory:</span> Upper respiratory infection, rhinitis, pharyngitis, cough. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Only 13% of oral dose reaches systemic circulation. <span class="typehead">Peak:</span> 12 h. <span class="typehead">Metabolism:</span> Minimal metabolism. <span class="typehead">Elimination:</span> 61% excreted in feces and 37% in urine. <span class="typehead">Half-Life:</span> 59 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor BP periodically; do trough readings just before scheduled dose when possible.</li>
<li>Monitor for S&amp;S of angioedema (may occur within 30 min or as long as 30 d after initial dose).</li>
<li>Lab tests: Monitor liver function, BUN &amp; creatinine, serum potassium, CBC with differential periodically.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Inform physician immediately of pregnancy.</li>
<li>Report episodes of dizziness especially associated with position changes.</li>
<li>Report swelling of lips, tongue, face, or feeling of obstruction in neck immediately.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>